Contra-indicated in organ transplant recipients. Orlistat interferes with the medicines used to prevent transplant rejection.
Obesity, weight reduction.
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions.
Contra-indicated in organ transplant recipients. Orlistat interferes with the medicines used to prevent transplant rejection.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of orlistat in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/28/2025